Browse the evidence

Genetic variants in GLP1R (e.g., rs6923761), GIPR (e.g., rs2287019, rs10423928), and TCF7L2 (rs7903146) significantly influence individual response to tirzepatide, affecting glycemic control, weight loss, and side effect profiles.

Your genes can affect how well tirzepatide works for you. If you have certain genetic variants, you might need a different dose or might experience different side effects. Talk to your doctor about genetic testing to personalize your treatment.

Pre-pregnancy lifestyle interventions (dietary restriction or exercise) initiated at least 9 weeks prior to conception reduce the risk of metabolic-associated fatty liver disease (MAFLD) in offspring of obese mothers, whereas interventions initiated only 1 week prior do not.

If you have obesity and plan to conceive, starting weight management 9+ weeks before trying to get pregnant is critical for your future child's liver health. Standard lifestyle changes may take too long, so discuss pre-pregnancy pharmacotherapy (like GLP-1 agonists) with your doctor to ensure you reach a healthy weight before conception.

Pre-pregnancy use of GLP-1 receptor agonists (e.g., liraglutide) or GLP-1/GIP co-agonists (e.g., tirzepatide) is a promising pharmacotherapeutic strategy for pre-pregnancy weight loss in obese women, potentially mitigating the intergenerational risk of MAFLD in offspring, provided sufficient wash-out periods are observed.

If lifestyle changes aren't enough to help you reach a healthy weight before pregnancy, talk to your doctor about GLP-1 medications. They are effective for weight loss and may improve your future child's liver health. Crucially, you must stop these medications well before trying to conceive to ensure they are out of your system.

Low-load resistance training (50% 1RM) produces greater acute muscle swelling (cellular hydration) than high-load resistance training (85% 1RM) when volume load is equated, primarily due to increased time under tension and training density.

If your goal is to maximize the 'pump' (acute muscle swelling) in a single workout, use lighter weights (around 50% of your max) and perform more reps until you can't do another one. This creates more time under tension and metabolic stress than heavy lifting, which may support muscle growth mechanisms, even though the total weight moved is the same.

A 14-day continuous adaptive infusion of the GLP-1/GCGR co-agonist G3215 produces significant weight loss (mean -2.39 kg) and reduced food intake in adults with overweight or obesity, with adverse effects mitigated by real-time dose adjustment.

This study shows that a 14-day continuous infusion of a specific hormone drug (G3215) can lead to about 2.4 kg of weight loss in adults with overweight or obesity. The drug works by reducing food intake and increasing energy expenditure. Side effects like nausea were common but manageable by adjusting the infusion rate. This approach might offer faster weight loss with better tolerability than current weekly injection options, though it requires wearing a pump for two weeks.

GLP-1 receptor agonists (e.g., semaglutide/Ozempic) suppress appetite and hunger signals by mimicking the hormone GLP-1, leading to significant weight loss but also causing a loss of the sensory and relational pleasure of eating.

GLP-1 drugs like semaglutide work by mimicking a hormone to reduce hunger and increase fullness, leading to weight loss. However, this comes with side effects like nausea and a reduced ability to enjoy food. The paper highlights that while these drugs can help with weight loss, they do not guarantee mental health improvements or self-acceptance, and weight regain is common if treatment stops. They are expensive and often used off-label.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce modest weight loss (2.3–5%) in breast cancer patients, which is significantly attenuated compared to non-cancer populations, likely due to concurrent endocrine therapy.

If you have breast cancer and are taking hormone-blocking therapy, GLP-1 drugs like semaglutide will likely help you lose some weight, but not as much as they do for people without cancer. Expect a modest loss (around 2-5%) rather than dramatic results. This is likely because your cancer treatment changes your metabolism. It appears safe regarding cancer recurrence, but discuss timing with your oncologist.

GLP-1 receptor agonist use in breast cancer patients does not increase the risk of cancer recurrence and may reduce cardiovascular morbidity.

For breast cancer patients, GLP-1 drugs appear safe regarding cancer recurrence. They may also offer significant cardiovascular protection, which is valuable since some cancer treatments can stress the heart. This benefit exists independently of weight loss.

Sympathomimetic agents (phentermine, phentermine/topiramate, naltrexone/bupropion) cause mild gastrointestinal side effects (constipation, dry mouth, nausea) with lower discontinuation rates compared to GLP-1 agonists.

If you take a sympathomimetic medication like phentermine or naltrexone/bupropion, you may experience mild side effects like constipation or dry mouth. These are generally less severe than the GI side effects associated with GLP-1 agonists. Stay hydrated and monitor your symptoms.

The cardiometabolic benefits of exercise, particularly on glucose regulation and inflammation, may be attenuated or dependent on weight loss in individuals with obesity.

Be aware that while exercise is beneficial, achieving weight loss may be necessary to fully improve glucose regulation and inflammation in obesity. However, do not stop exercising if weight loss is difficult; other benefits remain.

Carbohydrate-modified diets (low glycemic load, high fiber, or reduced-CHO) are more effective for weight loss or weight regain prevention in individuals with impaired glucose metabolism (prediabetes, IFG, or IGT) compared to those with normal glucose tolerance, supporting the hypothesis of precision nutrition based on glycemic status.

If you have prediabetes or impaired glucose tolerance, you may lose more weight or prevent weight regain by choosing a carbohydrate-modified diet (such as low glycemic load, high fiber, or reduced carbohydrate) compared to a standard high-carbohydrate diet. While the evidence is not yet definitive, this approach aligns with your body's likely insulin resistance. Consult a healthcare provider for testing and personalized guidance.

Women with type 2 diabetes treated with GLP-1 receptor agonists achieve significantly greater weight loss than men after 12 months, despite similar glycemic control improvements.

If you are a woman with Type 2 Diabetes on a GLP-1 agonist, you are statistically more likely to achieve significant weight loss (over 5% or 10%) than a man on the same medication class, particularly after 6-12 months. This does not mean men won't lose weight, but the magnitude of benefit tends to be greater in women. Glycemic control (HbA1c) improves similarly for both sexes.

Glucagon receptor (GCGR) agonism increases energy expenditure and promotes weight loss, particularly when combined with GLP-1R and/or GIPR agonism in dual or triple receptor agonists.

Current obesity treatments often lead to weight regain because they don't significantly increase energy expenditure. New drugs that activate the glucagon receptor (GCGR), either alone or combined with GLP-1/GIP drugs, are designed to boost energy expenditure and prevent this metabolic slowdown. While early results show significant weight loss (up to 24% in some trials), long-term clinical data is still emerging, and these are prescription medications requiring medical supervision.

In a mixed population of diabetic and non-diabetic patients, liraglutide (up to 3 mg) and semaglutide (up to 1 mg) produce statistically equivalent weight loss, contradicting findings from trials using higher doses or specific diabetic cohorts.

If you are using liraglutide or semaglutide at lower, standard starting-to-maintenance doses (up to 3mg and 1mg respectively), expect similar weight loss results. The perceived superiority of semaglutide in marketing often relies on higher doses (2.4mg) not used in this study. Focus on adherence and titration rather than switching solely for weight loss efficacy at these doses.

Higher baseline BMI and the presence of symptomatic comorbidities (specifically knee osteoarthritis or obstructive sleep apnoea) are associated with greater improvements in health utility scores following semaglutide 2.4 mg treatment.

If you have a higher BMI (over 35 or 40) and suffer from knee osteoarthritis or sleep apnea, semaglutide 2.4 mg once weekly may offer even greater improvements in your daily health quality of life than it would for someone with a lower BMI or fewer comorbidities.

Tirzepatide-supported digital weight loss programs achieve high mean weight loss (13.8% over 16 weeks) and high engagement rates, but proactive coaching messaging does not significantly improve weight loss outcomes compared to reactive or control models.

Tirzepatide delivers substantial weight loss (approx 14% in 16 weeks) even with minimal coaching interaction. You do not need to send frequent messages to your coach to lose weight; the medication is the primary driver. Focus on adherence to the dosing schedule and monitoring for side effects rather than trying to maximize engagement metrics.

In healthy adults, belonging to the second quartile of dietary glycemic index (GI) is associated with significantly lower odds of having elevated fasting blood glucose (hyperglycemia) compared to the lowest quartile.

You don't need to aim for the absolute lowest glycemic index foods to maintain healthy blood sugar. A moderate GI (second quartile) was associated with lower odds of high fasting blood glucose in this study. Focus on a balanced diet rather than extreme low-GI restrictions.

Shortened sleep duration (40% reduction for 4 nights) impairs adrenergic stimulation of lipolysis in postmenopausal women, reducing lipid efflux and potentially promoting abdominal adiposity independent of caloric intake.

If you are a postmenopausal woman struggling with abdominal fat despite diet and exercise, check your sleep. This research shows that even short-term sleep restriction (reducing sleep by 40% for just 4 nights) blunts your body's ability to break down fat (lipolysis). Prioritizing adequate sleep duration is a critical, often overlooked lever for managing abdominal adiposity in this demographic.

Myostatin and activin A inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) combined with GLP-1 agonists can increase lean mass and reduce fat mass more effectively than GLP-1 agonists alone.

New drugs targeting myostatin (like bimagrumab) are being tested alongside GLP-1s to build muscle while losing fat. These are currently in clinical trials and not yet widely available.

Semaglutide treatment in Type 2 Diabetes Mellitus patients significantly reduces HbA1c, fasting plasma glucose, and body weight while improving renal markers (ACR) over a 12-month period.

If you have Type 2 Diabetes, Semaglutide is a highly effective treatment for lowering blood sugar (HbA1c) and losing weight. It is taken as a once-weekly injection, starting at a low dose to minimize side effects like nausea. This treatment also helps protect kidney function by reducing albumin in the urine. Consistency is key, as benefits are maintained over time.

Tirzepatide (2.5 mg weekly) significantly improves glycemic control and reduces body weight in patients with type 2 diabetes during Ramadan fasting, with a favorable safety profile characterized by mild gastrointestinal side effects and no reported hypoglycemia.

If you have type 2 diabetes and plan to fast during Ramadan, tirzepatide (2.5 mg weekly) can help improve your blood sugar and weight without causing low blood sugar. You might experience mild stomach issues like nausea, but these are usually manageable and do not require stopping the medication or breaking your fast. Consult your doctor to ensure it fits your overall treatment plan.

Discontinuation or interruption of GLP-1 agonist therapy (semaglutide) leads to rapid weight regain and loss of cardiometabolic benefits, with patients regaining approximately two-thirds of lost weight within one year.

If you stop taking semaglutide, you will likely regain about two-thirds of the weight you lost and lose the heart and blood sugar benefits within a year. The drug works only as long as you take it. If you face a supply shortage or side effects, do not just stop; contact your provider immediately to switch to an alternative or manage the transition, as stopping leads to rapid regain.

GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.

Beyond weight loss, GLP-1 and GLP-1/GIP agonists may offer a mortality benefit compared to older weight loss drugs. This is a significant advantage for patients with obesity-related comorbidities.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce alcohol consumption, cravings, and alcohol-related hospitalizations in patients with Alcohol Use Disorder (AUD), particularly in obese subgroups.

If you have AUD, especially if you are obese or have Type 2 Diabetes, GLP-1 medications (like Semaglutide or Exenatide) are showing promise in reducing drinking and cravings. They work by changing how your brain rewards alcohol. While they are injections and can cause stomach issues, these side effects often fade. They are not yet the standard first-line treatment for all AUD, but they are a strong option to discuss with your doctor, particularly if other treatments haven't worked.